Cancer Margin Detection using Infrared Spectroscopy and Plasmon Resonance

使用红外光谱和等离子共振检测癌症边缘

基本信息

  • 批准号:
    8460487
  • 负责人:
  • 金额:
    $ 15.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-17 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cancer Margin Detection using Infrared Spectroscopy and Plasmon Resonance Abstract While surgical resection of cancerous tissue is the single most effective treatment for many forms of human cancer, the effectiveness of surgical procedures is limited by the difficulty of accurately recognizing tumor margins. Thus, the development of cancer specific molecular surface probes using ex vivo immunohistochemistry (IHC) is highly desirable. In the proposed studies, infrared (IR) spectroscopy with surface plasmon mesh enhancement will be used to assess normal versus adenocarcinoma tissues. This technology provides molecular signatures of biological tissue. Moreover, we will utilize labeled IR reporter molecular systems that consist of deuterated polyethylene glycol (dPEG) molecules synthetically attached to anti-tumor-associated-glycoprotein- 72 (anti-TAG-72), which selectively co-locates with adenocarcinoma tissue. This addresses the critical need for ex vivo differentiation between normal and cancerous tissue during surgery. IR methods, specifically with surface plasmon enhancement mesh materials that have highly reproducible IR absorbances, have the potential to overcome the limitations of current time consuming and labor intensive histological procedures. The specific molecular characterization of tumor margins will be more precise and reliable than current methods which depend on visual inspection of tumor biopsy material. Advanced IR methods can enable thorough analysis of resected tumor tissue, increase the quality of operating room histological analyses, and guide complete surgical removal of cancerous tissue. The approach of this proposal is to construct dPEG labeled adenocarcinomo-specific anti-TAG-72 monoclonal antibodies (MAbs) and assess the use of these reporters to identify tumor margins. The combination of IR spectroscopy and labeled anti-TAG MAbs has the ability to reduce assessment time and to supply timely feedback to the surgeon. It can also reduce the needless destruction or removal of normal tissues, improving patient outcomes. Anti-TAG MAbs have been shown to be highly selective for colon, breast, and gynecological cancer tissues making this methodology applicable to a range of medically important human cancers. Human tissue samples from colon, breast and pelvic/genital tissues for this proposed research will be provided by a surgical oncology team comprised of Drs. Martin, Povoski, and O'Malley. The pathology team, Drs. Hitchcock and Allen, will lead the development of histological and analytical methods including procedures for tissue staining with reporter constructs. Additionally, Coe will lead the surface plasmon IR enhancement methodology strategies. Team members (PI team and surgical team) have an established working relationship in MAb development in past years and this current proposal brings together additional expertise in IR and enhancement technology that has shown to be synergistic.
描述(由申请人提供):使用红外光谱和等离子体共振进行癌症边缘检测摘要虽然癌组织的手术切除是多种人类癌症的最有效治疗方法,但外科手术的有效性受到准确识别肿瘤边缘的困难的限制。因此,使用离体免疫组织化学(IHC)开发癌症特异性分子表面探针是高度期望的。在拟定的研究中,将使用具有表面等离子体网格增强的红外(IR)光谱来评估正常组织与腺癌组织。这项技术提供了生物组织的分子特征。此外,我们将利用标记的IR报告分子系统,该系统由合成连接到抗肿瘤相关糖蛋白-72(抗TAG-72)的氘代聚乙二醇(dPEG)分子组成,所述抗TAG-72选择性地与腺癌组织共定位。这解决了在手术期间离体区分正常组织和癌组织的关键需求。IR方法,特别是使用具有高度可再现IR光谱的表面等离子体增强网材料的IR方法,具有克服当前耗时且劳动密集型组织学程序的限制的潜力。肿瘤边缘的特异性分子表征将比目前依赖于肿瘤活检材料的目视检查的方法更精确和可靠。先进的IR方法可以对切除的肿瘤组织进行全面分析,提高手术室组织学分析的质量,并指导癌组织的完全手术切除。该方案的方法是构建dPEG标记的腺癌特异性抗TAG-72单克隆抗体(MAbs),并评估这些报告基因用于识别肿瘤边缘的用途。IR光谱和标记的抗TAG MAb的组合能够减少评估时间并向外科医生提供及时反馈。它还可以减少不必要的破坏或切除正常组织,改善患者的预后。抗TAG单克隆抗体已被证明对结肠癌、乳腺癌和妇科癌组织具有高度选择性,使得该方法适用于一系列医学上重要的人类癌症。用于本拟议研究的结肠、乳腺和盆腔/生殖器组织的人体组织样本将由Martin、Povoski和O 'Malley博士组成的外科肿瘤学团队提供。病理学团队希区柯克博士和艾伦博士将领导组织学和分析方法的开发,包括使用报告构建体进行组织染色的程序。此外,Coe将领导表面等离子体激元IR增强方法策略。团队成员(PI团队和手术团队)在过去几年中在MAb开发方面建立了工作关系,目前的提案汇集了IR和增强技术方面的额外专业知识,已证明具有协同作用。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Infrared metrics for fixation-free liver tumor detection.
用于免固定肝脏肿瘤检测的红外指标。
  • DOI:
    10.1021/jp4073087
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Chen,Zhaomin;Butke,Ryan;Miller,Barrie;Hitchcock,CharlesL;Allen,HeatherC;Povoski,StephenP;MartinJr,EdwardW;Coe,JamesV
  • 通讯作者:
    Coe,JamesV
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heather Cecile Allen其他文献

Heather Cecile Allen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Heather Cecile Allen', 18)}}的其他基金

Cancer Margin Detection using Infrared Spectroscopy and Plasmon Resonance
使用红外光谱和等离子共振检测癌症边缘
  • 批准号:
    8283512
  • 财政年份:
    2012
  • 资助金额:
    $ 15.11万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 15.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了